WuXi AppTec Confirms Board and Executive Line-Up for Fourth Term

WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) has issued an announcement.

WuXi AppTec has confirmed a broad slate of board and senior management decisions at the first meeting of its fourth board session, effective April 28, 2026. The company re-elected founder Dr. Ge Li as chairman, and re-appointed him as president and chief executive officer for the duration of the fourth board term.

The board also renewed the mandates of co-chief executive officers Dr. Minzhang Chen and Dr. Steve Qing Yang, signaling continuity in top operational leadership. In addition, WuXi AppTec re-appointed Zhaohui Zhang and appointed long-time legal and compliance executive Dr. Hao Wu as vice presidents, reinforcing management depth as the company navigates its next phase of growth and governance under the new board term.

The most recent analyst rating on (HK:2359) stock is a Buy with a HK$150.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.

More about WuXi AppTec Co., Ltd. Class H

WuXi AppTec Co., Ltd. is a China-based contract research, development and manufacturing organization serving the global pharmaceutical and biotech industries. The company provides integrated R&D and manufacturing services that support drug discovery, development and commercialization for international life sciences customers.

Average Trading Volume: 4,684,003

Technical Sentiment Signal: Buy

Current Market Cap: HK$339.2B

For an in-depth examination of 2359 stock, go to TipRanks’ Overview page.